Receives $249,500 in Additional Financing
YONKERS, N.Y., Oct. 28 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), announced today that it has commenced a Phase IIb efficacy study for AVR123 in wound healing.
The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen Germany, led by Eckhart Kampgen, M.D., Associate Professor for Strategies of Cellular Immunotherapy at the Department of Dermatology. Dr. Kampgen is leading the Immunomonitoring, RNA and Melanoma Division at the hospital. He has over 80 peer-reviewed publications and has participated as Principal Investigator or Sub-Investigator in more than 20 Phase I, II and III clinical studies since 1995.
The primary objective of this study is to evaluate the effect of AVR123, applied topically, on the rate and quality of healing of wounds. According to the protocol, patients enrolled in the study will include individuals with a variety of wounds and dermatologic conditions.
AVR123 is a topical formulation of ARV118 which is currently being investigated for the systemic treatment of cancer related clinical cachexia. This compound has well-documented anti-inflammatory and wound healing activities. Results of a Phase I, open label, dose-escalating study indicated that topical AVR123 is well-tolerated, showing no dose-limiting toxicities. Initial observations of accelerated wound healing in a pig study at the University of Miami suggest that AVR123 may represent an important advance in the management of wounds.
Stephen Elliston, President and Chief Executive Officer of Advanced
Viral, stated, "This trial has been designed to provide further evidence to
substantiate encouraging preliminary results seen in the initial phase of
the study, which was not completed due to the death of the study's
Principal Investigator. We are highly fortunate to have Dr. Kampgen, a
prestigious leader in the dermatological field
|SOURCE Advanced Viral Research Corp.|
Copyright©2008 PR Newswire.
All rights reserved